{"count": 12, "results": [{"_id": "37216202", "pmid": 37216202, "title": "COVID-19 update: Metformin to prevent long COVID?", "journal": "Med Lett Drugs Ther", "date": "2023-05-29T00:00:00Z", "doi": "10.58347/tml.2023.1677e", "meta_date_publication": "2023 May 29", "meta_volume": "65", "meta_issue": "1677", "meta_pages": "87-88", "score": 50270.18, "text_hl": "@DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@COVID-19@@@ update: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ to prevent @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long COVID@@@?", "citations": {"NLM": "COVID-19 update: Metformin to prevent long COVID? Med Lett Drugs Ther. 2023 May 29;65(1677):87-88. PMID: 37216202", "BibTeX": "@article{37216202, title={COVID-19 update: Metformin to prevent long COVID?}, journal={Med Lett Drugs Ther}, volume={65}, number={1677}, pages={87-88}}"}}, {"_id": "37194484", "pmid": 37194484, "title": "Metformin as a potential treatment for COVID-19.", "journal": "Expert Opin Pharmacother", "authors": ["MCCarthy MW"], "date": "2023-05-18T00:00:00Z", "doi": "10.1080/14656566.2023.2215385", "meta_date_publication": "2023 May 18", "meta_volume": "", "meta_issue": "", "meta_pages": "1-5", "score": 50263.434, "text_hl": "Recent work suggests @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may also serve as a therapeutic option for @SPECIES_9606 @@@patients@@@ with @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@COVID-19@@@ as well as those with @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@post-acute sequelae of SARS-CoV-2 infection@@@, known more commonly as '@<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long COVID-19@@@.' ", "citations": {"NLM": "MCCarthy MW. Metformin as a potential treatment for COVID-19. Expert Opin Pharmacother. 2023 May 18;():1-5. PMID: 37194484", "BibTeX": "@article{37194484, title={Metformin as a potential treatment for COVID-19.}, author={MCCarthy MW}, journal={Expert Opin Pharmacother}, pages={1-5}}"}}, {"_id": "37290779", "pmid": 37290779, "title": "Covid-19: Metformin reduces the risk of developing long term symptoms by 40%, study finds.", "journal": "BMJ", "authors": ["Wise J"], "date": "2023-06-08T00:00:00Z", "doi": "10.1136/bmj.p1306", "meta_date_publication": "2023 Jun 8", "meta_volume": "381", "meta_issue": "", "meta_pages": "p1306", "score": 50260.258, "text_hl": "@DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@Covid-19@@@: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ reduces the risk of developing @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long@@@ term symptoms by 40%, study finds.", "citations": {"NLM": "Wise J. Covid-19: Metformin reduces the risk of developing long term symptoms by 40%, study finds. BMJ. 2023 Jun 8;381():p1306. PMID: 37290779", "BibTeX": "@article{37290779, title={Covid-19: Metformin reduces the risk of developing long term symptoms by 40%, study finds.}, author={Wise J}, journal={BMJ}, volume={381}, pages={p1306}}"}}, {"_id": "37715729", "pmid": 37715729, "title": "Treatable traits for long COVID.", "journal": "Respirology", "authors": ["Lewthwaite H", "Byrne A", "Brew B", "Gibson PG"], "date": "2023-09-16T00:00:00Z", "doi": "10.1111/resp.14596", "meta_date_publication": "2023 Sep 16", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50259.95, "text_hl": "While a single study reported @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ as effective for @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long COVID@@@ prevention, the findings need to be replicated and consensus is required around how to define @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long COVID@@@ as a clinical trial endpoint. ", "citations": {"NLM": "Lewthwaite H, Byrne A, Brew B, Gibson PG. Treatable traits for long COVID. Respirology. 2023 Sep 16;():. PMID: 37715729", "BibTeX": "@article{37715729, title={Treatable traits for long COVID.}, author={Lewthwaite H and Byrne A and Brew B and Gibson PG}, journal={Respirology}}"}}, {"_id": "39287394", "pmid": 39287394, "title": "Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program.", "journal": "Diabetes Care", "authors": ["Johnson SG", "Abedian S", "Stürmer T", "Huling JD", "Lewis V C", "Buse JB", "Brosnahan SB", "Mudumbi PC", "Erlandson KM", "McComsey GA", "Arnold J", "Wiggen TD", "Wong R", "Murphy S", "Rosen C", "Kaushal R", "Weiner MG", "Bramante C", "RECOVER PCORnet EHR Cohort and the N3C Consortium"], "date": "2024-09-17T00:00:00Z", "doi": "10.2337/DCa24-0032", "meta_date_publication": "2024 Sep 17", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50259.81, "text_hl": "Incident @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@PASC@@@ by diagnosis code was 1.6% @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ vs. 2.0% comparator in the N3C, and 2.1% @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ vs. 2.5% comparator in PCORnet. ", "citations": {"NLM": "Johnson SG, Abedian S, Stürmer T, Huling JD, Lewis V C, Buse JB, Brosnahan SB, Mudumbi PC, Erlandson KM, McComsey GA, Arnold J, Wiggen TD, Wong R, Murphy S, Rosen C, Kaushal R, Weiner MG, Bramante C, RECOVER PCORnet EHR Cohort and the N3C Consortium. Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program. Diabetes Care. 2024 Sep 17;():. PMID: 39287394", "BibTeX": "@article{39287394, title={Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program.}, author={Johnson SG and Abedian S and Stürmer T and Huling JD and Lewis V C and Buse JB and Brosnahan SB and Mudumbi PC and Erlandson KM and McComsey GA and Arnold J and Wiggen TD and Wong R and Murphy S and Rosen C and Kaushal R and Weiner MG and Bramante C and RECOVER PCORnet EHR Cohort and the N3C Consortium}, journal={Diabetes Care}}"}}, {"_id": "37333243", "pmid": 37333243, "pmcid": "PMC10275003", "title": "Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial", "journal": "medRxiv", "authors": ["Bramante CT", "Beckman KB", "Mehta T", "Karger AB", "Odde DJ", "Tignanelli CJ", "Buse JB", "Johnson DM", "Watson RHB", "Daniel JJ", "Liebovitz DM", "Nicklas JM", "Cohen K", "Puskarich MA", "Belani HK", "Siegel LK", "Klatt NR", "Anderson B", "Hartman KM", "Rao V", "Hagen AA", "Patel B", "Fenno SL", "Avula N", "Reddy NV", "Erickson SM", "Fricton RD", "Lee S", "Griffiths G", "Pullen MF", "Thompson JL", "Sherwood N", "Murray TA", "Rose MR", "Boulware DR", "Huling JD", "COVID-OUT study team"], "date": "2023-06-07T00:00:00Z", "doi": "10.1101/2023.06.06.23290989", "meta_date_publication": "2023 Jun 7", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50258.727, "text_hl": "The clinical outcomes showed that immediate release @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ reduced the relative risk of emergency department visits / hospitalization / and @DISEASE_Death @DISEASE_MESH:D003643 @@@death@@@ through 14-days by 42%; the relative risk of hospitalization or @DISEASE_Death @DISEASE_MESH:D003643 @@@death@@@ through 28-days by 58%; and the relative risk of @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@Long COVID@@@ through 10 months by over 40%.", "citations": {"NLM": "Bramante CT, Beckman KB, Mehta T, Karger AB, Odde DJ, Tignanelli CJ, Buse JB, Johnson DM, Watson RHB, Daniel JJ, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Siegel LK, Klatt NR, Anderson B, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Fricton RD, Lee S, Griffiths G, Pullen MF, Thompson JL, Sherwood N, Murray TA, Rose MR, Boulware DR, Huling JD, COVID-OUT study team. Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial medRxiv. 2023 Jun 7;():. PMID: 37333243", "BibTeX": "@article{37333243, title={Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial}, author={Bramante CT and Beckman KB and Mehta T and Karger AB and Odde DJ and Tignanelli CJ and Buse JB and Johnson DM and Watson RHB and Daniel JJ and Liebovitz DM and Nicklas JM and Cohen K and Puskarich MA and Belani HK and Siegel LK and Klatt NR and Anderson B and Hartman KM and Rao V and Hagen AA and Patel B and Fenno SL and Avula N and Reddy NV and Erickson SM and Fricton RD and Lee S and Griffiths G and Pullen MF and Thompson JL and Sherwood N and Murray TA and Rose MR and Boulware DR and Huling JD and COVID-OUT study team}, journal={medRxiv}}"}}, {"_id": "37302406", "pmid": 37302406, "title": "Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.", "journal": "Lancet Infect Dis", "authors": ["Bramante CT", "Buse JB", "Liebovitz DM", "Nicklas JM", "Puskarich MA", "Cohen K", "Belani HK", "Anderson BJ", "Huling JD", "Tignanelli CJ", "Thompson JL", "Pullen M", "Wirtz EL", "Siegel LK", "Proper JL", "Odde DJ", "Klatt NR", "Sherwood NE", "Lindberg SM", "Karger AB", "Beckman KB", "Erickson SM", "Fenno SL", "Hartman KM", "Rose MR", "Mehta T", "Patel B", "Griffiths G", "Bhat NS", "Murray TA", "Boulware DR"], "date": "2023-06-08T00:00:00Z", "doi": "10.1016/S1473-3099(23)00299-2", "meta_date_publication": "2023 Jun 8", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50255.047, "text_hl": "INTERPRETATION: @SPECIES_9606 @@@Outpatient@@@ treatment with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ reduced @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long COVID@@@ incidence by about 41%, with an absolute reduction of 4 1%, compared with placebo. ", "citations": {"NLM": "Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, Belani HK, Anderson BJ, Huling JD, Tignanelli CJ, Thompson JL, Pullen M, Wirtz EL, Siegel LK, Proper JL, Odde DJ, Klatt NR, Sherwood NE, Lindberg SM, Karger AB, Beckman KB, Erickson SM, Fenno SL, Hartman KM, Rose MR, Mehta T, Patel B, Griffiths G, Bhat NS, Murray TA, Boulware DR. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023 Jun 8;():. PMID: 37302406", "BibTeX": "@article{37302406, title={Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.}, author={Bramante CT and Buse JB and Liebovitz DM and Nicklas JM and Puskarich MA and Cohen K and Belani HK and Anderson BJ and Huling JD and Tignanelli CJ and Thompson JL and Pullen M and Wirtz EL and Siegel LK and Proper JL and Odde DJ and Klatt NR and Sherwood NE and Lindberg SM and Karger AB and Beckman KB and Erickson SM and Fenno SL and Hartman KM and Rose MR and Mehta T and Patel B and Griffiths G and Bhat NS and Murray TA and Boulware DR}, journal={Lancet Infect Dis}}"}}, {"_id": "39796218", "pmid": 39796218, "title": "Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits.", "journal": "Int J Mol Sci", "authors": ["Yip JMX", "Chiang GSH", "Lee ICJ", "Lehming-Teo R", "Dai K", "Dongol L", "Wang LY", "Teo D", "Seah GT", "Lehming N"], "date": "2025-01-03T00:00:00Z", "doi": "10.3390/ijms26010364", "meta_date_publication": "2025 Jan 3", "meta_volume": "26", "meta_issue": "1", "meta_pages": "", "score": 50252.016, "text_hl": "To promote viral replication in all infected @SPECIES_9606 @@@human@@@ cells, @SPECIES_2697049 @@@SARS-CoV-2@@@ stimulates the infected liver cells to produce @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ and to export it into the blood stream, which can cause @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ in @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long COVID@@@ @SPECIES_9606 @@@patients@@@, and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, which reduces the levels of @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ in the blood, was shown to cut the incidence rate of @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long COVID@@@ in half for all @SPECIES_9606 @@@patients@@@ recovering from @SPECIES_2697049 @@@SARS-CoV-2@@@. ", "citations": {"NLM": "Yip JMX, Chiang GSH, Lee ICJ, Lehming-Teo R, Dai K, Dongol L, Wang LY, Teo D, Seah GT, Lehming N. Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits. Int J Mol Sci. 2025 Jan 3;26(1):. PMID: 39796218", "BibTeX": "@article{39796218, title={Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits.}, author={Yip JMX and Chiang GSH and Lee ICJ and Lehming-Teo R and Dai K and Dongol L and Wang LY and Teo D and Seah GT and Lehming N}, journal={Int J Mol Sci}, volume={26}, number={1}}"}}, {"_id": "38113020", "pmid": 38113020, "title": "Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review.", "journal": "Infection", "authors": ["Fernández-de-Las-Peñas C", "Torres-Macho J", "Catahay JA", "Macasaet R", "Velasco JV", "Macapagal S", "Caldararo M", "Henry BM", "Lippi G", "Franco-Moreno A", "Notarte KI"], "date": "2023-12-19T00:00:00Z", "doi": "10.1007/s15010-023-02154-0", "meta_date_publication": "2023 Dec 19", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50251.844, "text_hl": "Three studies investigating the effects of other medication such as @CHEMICAL_Dexamethasone @CHEMICAL_MESH:D003907 @@@Dexamethasone@@@ (n = 2) or @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ (n = 1) found positive results of these medications for preventing @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long-COVID@@@. ", "citations": {"NLM": "Fernández-de-Las-Peñas C, Torres-Macho J, Catahay JA, Macasaet R, Velasco JV, Macapagal S, Caldararo M, Henry BM, Lippi G, Franco-Moreno A, Notarte KI. Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review. Infection. 2023 Dec 19;():. PMID: 38113020", "BibTeX": "@article{38113020, title={Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review.}, author={Fernández-de-Las-Peñas C and Torres-Macho J and Catahay JA and Macasaet R and Velasco JV and Macapagal S and Caldararo M and Henry BM and Lippi G and Franco-Moreno A and Notarte KI}, journal={Infection}}"}}, {"_id": "37534972", "pmid": 37534972, "title": "Experimental drugs in randomized controlled trials for long-COVID: what's in the pipeline? A systematic and critical review.", "journal": "Expert Opin Investig Drugs", "authors": ["Yong SJ", "Halim A", "Halim M", "Ming LC", "Goh KW", "Alfaresi M", "AlShehail BM", "Al Fares MA", "Alissa M", "Sulaiman T", "Alsalem Z", "Alwashmi ASS", "Khamis F", "Al Kaabi NA", "Albayat H", "Alsheheri A", "Garout M", "Alsalman J", "Alfaraj AH", "Alhajri M", "Dhama K", "Alburaiky LM", "Alsanad AH", "AlShurbaji AT", "Rabaan AA"], "date": "2023-08-04T00:00:00Z", "doi": "10.1080/13543784.2023.2242773", "meta_date_publication": "2023 Aug 4", "meta_volume": "", "meta_issue": "", "meta_pages": "1-13", "score": 50249.85, "text_hl": "Currently, @CHEMICAL_poly(I).poly(c12_U) @CHEMICAL_MESH:C047490 @@@rintatolimod@@@ appears to have modest to high potential for treating the @DISEASE_Fatigue_Syndrome_Chronic @DISEASE_MESH:D015673 @@@myalgic encephalomyelitis/chronic fatigue syndrome@@@ (@DISEASE_Fatigue_Syndrome_Chronic @DISEASE_MESH:D015673 @@@ME/CFS@@@) subtype, LTY-100 and @CHEMICAL_N_N'_bis(2_(1H_imidazol_2_yl)ethyl)pentanediamide @CHEMICAL_MESH:C000723313 @@@Treamid@@@ for @DISEASE_Pulmonary_Fibrosis @DISEASE_MESH:D011658 @@@pulmonary fibrosis@@@ subtype, and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for general @<m>DISEASE_Post_Acute_COVID_19_Syndrome</m> @DISEASE_MESH:D000094024 @@@long-COVID@@@ prevention.", "citations": {"NLM": "Yong SJ, Halim A, Halim M, Ming LC, Goh KW, Alfaresi M, AlShehail BM, Al Fares MA, Alissa M, Sulaiman T, Alsalem Z, Alwashmi ASS, Khamis F, Al Kaabi NA, Albayat H, Alsheheri A, Garout M, Alsalman J, Alfaraj AH, Alhajri M, Dhama K, Alburaiky LM, Alsanad AH, AlShurbaji AT, Rabaan AA. Experimental drugs in randomized controlled trials for long-COVID: what's in the pipeline? A systematic and critical review. Expert Opin Investig Drugs. 2023 Aug 4;():1-13. PMID: 37534972", "BibTeX": "@article{37534972, title={Experimental drugs in randomized controlled trials for long-COVID: what's in the pipeline? A systematic and critical review.}, author={Yong SJ and Halim A and Halim M and Ming LC and Goh KW and Alfaresi M and AlShehail BM and Al Fares MA and Alissa M and Sulaiman T and Alsalem Z and Alwashmi ASS and Khamis F and Al Kaabi NA and Albayat H and Alsheheri A and Garout M and Alsalman J and Alfaraj AH and Alhajri M and Dhama K and Alburaiky LM and Alsanad AH and AlShurbaji AT and Rabaan AA}, journal={Expert Opin Investig Drugs}, pages={1-13}}"}}]}